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Abstract A wide variety of pathologies can produce focal
lesions within the spleen. These are being more frequently
encountered as imaging technology improves. It is vital that
radiologists are aware of these pathologies to enable accurate
diagnosis. The role of ultrasound contrast in splenic disease
will be discussed and illustrated with cases likely to be
encountered by general and abdominal radiologists.
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Introduction
Ultrasound contrast agents have been shown to be
extremely accurate for detection and characterisation of
focal hepatic lesions. Given that isolated splenic pathology
is relatively uncommon compared with focal hepatic
lesions, the spleen has received less attention. However a
number of studies related to the spleen have recently been
published and show promising results. The purpose of this
article is to provide an introduction to contrast-enhanced
ultrasound of the spleen, including a review of the evidence
and an illustration of common pathologies.
Ultrasound contrast agents
Modern ultrasound contrast agents are composed of
perflutren gas within a stabilising lipid shell. These agents
oscillate at a harmonic frequency, and this harmonic can be
isolated to produce an image that is almost solely related to
the contrast agent with little input from the underlying
tissue. Ultrasound contrast agents (UCAs) are administered
intravenously, are purely intravascular due to their size of
5–10 microns and lack the extracellular phase of CT and
MRI contrast agents. Following injection, continuous
scanning can be performed, and the phases of contrast are
broadly divided into arterial (10–25 s), portal venous (30–
120 s) and late phases (over 120 s) [1], although some
variability occurs depending upon the patient’s cardiac
function. Further injections can be performed after a delay
of 5–10 min. Usually only a small proportion of each dose
is injected. For example, Definity (Lantheus, North Bill-
erica, MA) is packaged in a 1.5 ml vial, but typical
injections are 0.2–0.4 cc each followed by a 5–10 ml saline
flush. SonoVue (Bracco Milano, Italy) is a sulphur
hexofluride agent licensed for use in Europe and is typically
diluted in 5 cc of normal saline before being administered
in 1.0–2.5 cc aliquots. Splitting the dose allows multiple
runs to be performed per vial and also minimises
attenuation of deep structures that can occur with high
contrast doses. Further information regarding UCAs is
available in Guidelines produced by the European Federa-
tion of Societies for Ultrasound in Medicine and Biology
(EFSUMB) [2].
The strength of ultrasound contrast agents is their ability
to depict both the macrocirculation and the microcircula-
tion. Signal is obtained simply due to the presence of the
contrast. It does not matter if the bubble is moving quickly,
slowly or is stationary. By comparison Doppler ultrasound
can only assess the macrocirculation.
UCAs can be safely administered in renal impairment
and are not nephrotoxic [3]. Contraindications include
recent myocardial infarction, unstable angina, and recent
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arrhythmias, pulmonary hypertension, and left to right or
bidirectional cardiac shunts [3].
Lesion detection
In the liver UCAs have been shown to have a sensitivity of
approximately 80% for detecting hepatic metastases [4],
which is comparable to multiphase multidetector CT. By
comparison, metastatic disease to the spleen is uncommon,
occurring in 1% of advanced visceral malignancy [5] and
so UCAs do not have a practical role in screening the
spleen in patients with visceral tumours. The spleen is
involved in 30–40% of patients with systemic lymphoma
[6, 7], and if UCAs are to have a role in lesion detection,
this is the most likely indication. It has been shown that
ultrasound has a higher sensitivity than positron emission
tomography and CT for detecting splenic involvement in
systemic lymphoma [8]. However a recent study [9] found
that UCAs did not offer a significant advantage over B-
mode ultrasound alone. Based upon the current body of
evidence there appears to be no role for UCAs in lesion
detection in the spleen.
Lesion characterisation
B mode accuracy in characterising focal splenic lesions is
only moderate at approximately 50% [10], and Doppler
ultrasound is of little assistance. In a study examining 98
aetiologically proven focal splenic lesions [11], Doppler
ultrasound was disappointing with 68.4% of lesions
appearing ‘avascular’, including 40.0% of metastases,
Fig. 1 Hypoechoic slightly het-
erogenous splenic haemangioma
(arrows) on B mode ultrasound
(a), has homogenous enhance-
ment 30 s after contrast
administration (b), remains
isoenhancing at 2 min (c), but
develops washout at 3 min
30 s (d)
516 Insights Imaging (2011) 2:515–524Fig. 2 Well defined echogenic
haemangioma (arrows)o nB
mode (a) is homogenously
slightly hypoenhancing at 20 s
(b) and at 90 s (c) and retains
contrast into the late phase at
4 min (d)
Fig. 3 Large hypoechoic haemangioma (arrows) on B mode (a) with a small amount of normal spleen at the deep aspect (arrowheads). It has
homogenous enhancement at 15 s (b) and retains contrast into the late phase (c)
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tumours and so did not allow accurate differentiation of
benign and malignant pathologies.
A relatively large study by Stang et al. [10] examined
147 focal splenic lesions and used four readers, two blinded
to all information apart from B mode and CEUS, and two
readers who were given clinical information in addition to
the images. Fully blinded reporters had an accuracy of 51
and 43% on B mode, which increased to 83 and 81%
following CEUS. The readers with access to clinical
information performed better on B mode with an accuracy
of 70 and 74%, which further increased to 92 and 91%
following CEUS. This study shows that to correctly classify
focal splenic pathologies, it is vital to know the patient’s
clinical context and to administer contrast. Overall the non-
clinically blinded readers had sensitivity, specificity, posi-
tive and negative predictive value of 100% (79 of 79
malignant lesions), 83.8% (57 of 68 benign lesions), 87.8%
(79 of 90 lesions) and 100% (57 of 57 lesions) respectively,
which is similar to the results for
18F-FDG PET/CT [12].
These results have been supported by another study
involving 48 patients with 75 focal splenic lesions [13]
that found a sensitivity, specificity and accuracy of 91.1,
95.0 and 92.0% respectively. The diagnostic utility of
CEUS of the spleen is further supported by other
investigators [14].
Fig. 4 Hypoechoic heteroge-
nous focal splenic mass
(arrows) on B mode (a)i s
biopsy-proven diffuse B cell
lymphoma. It has homogenous
enhancement at 10 s (b), begins
to washout by 30 s (c) and has
clearly washed out by 60 s (d)
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splenic lesions [10, 15]:
1. Lesions that enhance in the arterial phase and rapidly
washout
2. Lesions that enhance in the arterial phase with
enhancement continuing into the parenchymal and late
phases or with late phase washout
3. Lesions that do not enhance at any stage
The first pattern is a malignant enhancement pattern while
patterns 2 and 3 are seen in benign lesions. Based upon the
experience with liver imaging [16, 17], the high specificity of
late phase washout as described in the current studies is likely
to decline in the future, albeit to a small degree as atypical
lesions breaking the rules are described. The key to
differentiating benign from malignant washout is related to
timing, with malignant lesions washing out rapidly and benign
pathologies generally showing later, more gradual washout.
Examples of splenic haemangiomas demonstrating late phase
washout have recently been described in the literature [18]
and have been encountered in our practice (Fig. 1). The
presence of irregular intralesional vessels is associated with
malignant lesions as is a ‘dotted’ appearance in the
parenchymal phase [10]. While these findings may support
Fig. 5 Lymphomatous mass bulging from the spleen (arrows) on B mode (a) contains islands of enhancement at 13 s (b) and more diffuse
enhancement at 3 min 15 s (c) that is markedly less than normal spleen
Fig. 6 Melanoma metastasis (arrows) is hypoenhancing at 33 s (a), with washout at 1 min 36 s (b) and markedly hypoenhancing at 3 min 23 s (c)
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in our experience are subject to interobserver variation, while
the binary decision of rapid lesion washout versus no washout
is accurate, reproducible and serves as the basis for classifying
lesions as malignant or benign respectively.
Haemangioma
Haemangiomas are the most frequent primary splenic tumour.
They are benign and may be either cavernous or capillary and
as such may appear hypoechoic or echogenic on B mode
ultrasound.WithCEUStheytypicallyenhancediffuselyinthe
arterial phase [10]. The peripheral nodular enhancement with
an early incomplete ring seen with hepatic haemangiomas is
uncommonly encountered with splenic haemangiomas. The
enhancement may be homogenous or heterogenous and the
lesions retain contrast into the late phase to be isoechoic to
normal splenic parenchyma (Fig. 2). Large haemangiomas
may retain so much contrast that they obscure the deep
aspect of the spleen (Fig. 3). Rarely haemangiomas can show
washout in the delayed phase, and in our experience this
generally occurs late unlike the early rapid washout seen
with malignant lesions. As a technical point, when examin-
ing large lesions or deep lesions, it is best to inject only small
volumes of UCAs to minimise attenuation in the late phase
that may obscure the region of interest.
Lymphoma
As previously mentioned the spleen is involved in 30–
40% of cases of systemic lymphoma with a variety of B
mode sonographic appearances, including small nodules,
large masses and bulky infiltrative disease [19]. Lesions
are typically hypoechoic relative to normal splenic
parenchyma. In the arterial phase lymphoma may be
isoenhancing or hypoenhancing relative to normal spleen
[15] and is typically diffuse and with internal irregular
vessels [10]. Homogenous arterial enhancement is more
typical than heterogenous enhancement [9]( F i g .4). With
increasing delay they become more conspicuous and
progressively more hypoenhancing relative to normal
spleen [8, 20]. Late phase imaging can demonstrate the
Fig. 8 Wedge shaped splenic infarct with no enhancement
Fig. 7 A tuberculous abscess
(arrows) appears solid on B
mode (a) and has a subtle hyper-
enhancing capsule (arrowheads)
at 7 s (b)w i t hn oc e n t r a l
enhancement
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not enhance during the early phase (Fig. 5). This
microcirculation is usually seen as fine enhancing regions
relative to normal splenic parenchyma that lacks the
chaotic irregular vessels representing the macrocirculation
that may be seen during the arterial phase.
Metastases
Splenic metastases from visceral tumours occur most fre-
quently secondary to lung cancer, malignant melanoma and
breast cancer [21]. Isolated splenic metastases are rare but
have been described [22, 23]. Splenic metastases typically
enhance slightly less than or to a similar degree to normal
spleen and are often complex lesions followed by rapid
washout (Fig. 6). Similar to lymphoma, late phase imaging
can depict microcirculation in areas of viable tumour that
may have otherwise been mistaken for necrosis, which is
particularly important when assessing response to chemo-
therapy. It is impossible to differentiate lymphoma from
metastases on the splenic CEUS appearance alone, although
necrosis is more commonly seen in metastatic disease.
Abscess
Splenic abscess may relate to Gram-negative or Gram-
positive bacteria with fungal abscesses virtually con-
fined to heavily immunosuppressed populations. A
typical bacterial abscess does not enhance during any
phase while a fungal or tuberculous abscess is hypo-
enhancing during the early and the late phases and with
no enhancement or microcirculation depicted within
areas of pus [10]. However other authors describe an
enhancing rim and occasional internal septations [20]
(Fig. 7). In our experience it is impossible to differentiate
an abscess with an enhancing capsule from a tumour with
central necrosis but viable peripheral tumour rind. In these
cases clinical correlation is vital, and histologic/microbi-
ological sampling may need to be considered. This is
similar to the experience in the liver with CEUS alone
struggling to differentiate many malignant and inflamma-
tory lesions [17, 24].
Infarct
Splenic infarcts can have a variable appearance on B mode
ultrasound but are typically hypoechoic and wedge shaped
with the echogenicity increasing with time. However they can
alsodemonstrate parenchymalheterogeneityandoccasionally
appear mass like. With ultrasound contrast they do not
enhance [13], are well defined and often the wedge shaped
nature of the lesion is better appreciated (Fig. 8). In our
experience it is not uncommon to see internal vessels within
an infarct representing clot lysis with reperfusion of large
vessels (Fig. 9). These vessels are typically smooth, regular
and well formed making them easily distinguishable from
the irregular chaotic vessels seen with neoplasia.
Cysts
A simple cyst is easily diagnosed on B mode ultrasound,
however cysts complicated by haemorrhage or infection
may be more challenging. CEUS shows cysts to be non-
enhancing structures that are well defined and lack the
enhancing periphery seen with necrotic tumours and
abscesses (Fig. 10) enabling confident diagnosis.
Fig. 9 A subacute splenic in-
farct mimics an almost spherical
mass on B mode (arrows)( a)
with its wedge shaped nature
better appreciated at 65 s with a
well defined smooth and regular
recanalised vessel at its apex (b)
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Sarcoid is an idiopathic non-caseating granulomatous
disease most commonly involving the pulmonary
parenchyma and mediastinal lymph nodes, although
disease may involve any organ. Splenic sarcoid may
manifest as splenomegaly and/or multiple splenic
parenchymal nodules and is seen in approximately
Fig. 10 Anechoic cyst (short
arrow) with a septation (long
arrow)( a) in a patient with
previous colorectal carcinoma.
There is no enhancement within
the cyst or the avascular septa-
tion at 12 s (b) or 2 min 30 s (c).
A different patient with a heter-
ogenous complex cyst (callipers
on B mode, d). There is no
enhancement within this cyst or
its dependent debris and no
enhancing capsule (e 32 s, f 66
s, g 2 min 37 s)
522 Insights Imaging (2011) 2:515–52415% of patients with sarcoid [25]. The nodules are
typically small, multiple and frequently associated with
intra-abdominal adenopathy [26]. We have been able to
find only a single case report describing the CEUS
appearance of splenic sarcoid [27], and this article
describes the lesions as being non-enhancing during all
phases. In our experience we have found that the
granulomas do enhance in the arterial phase but less than
normal splenic parenchyma, and they remain hypoen-
hancing throughout the parenchymal and late phases
(Fig. 11). The degree of hypoenhancement compared to
normal spleen was relatively constant with no definite
comparative washout. In this case clinical correlation and
angiotensin-converting enzyme (ACE) assay were critical
to establishing a confident diagnosis.
Conclusion
Contrast-enhanced ultrasound has been shown to be a safe
and accurate method to differentiate benign from malignant
focal splenic lesions particularly when coupled with
appropriate clinical information. There is enough evidence
to support its use as a first line test, particularly for focal
splenic lesions detected at B mode ultrasound when it will
often provide a diagnosis. The small proportion of lesions
Fig. 11 Innumerable hypoe-
choic granulomas (a)i na
mildly enlarged spleen in an 18-
year-old female with sarcoid.
The granulomas are hypoen-
hancing in the arterial phase (b:
23 s), and remain hypoenhanc-
ing in the parenchymal phase (c:
1 min 45 s) and in the late phase
(d: 3 min) with no definite
washout compared to the back-
ground spleen
Insights Imaging (2011) 2:515–524 523that remain indeterminate following CEUS can subsequent-
ly be investigated with CT, MRI or nuclear medicine where
appropriate.
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